Vaccination of Patients With Metastatic Renal Cell Carcinoma With Autologous Dendritic Cells Pulsed With Autologous Tumor Antigens in Combination With Interleukin-2: A Phase 1 Study

Journal of Immunotherapy

Volumn 25, Issue 6, 2002, Pages 500-508

  Oosterwijk Wakka, Jeannette C ^a   Tiemessen, Dorien M ^a   Bleumer, Ivar ^a   de Vries, I Jolanda M ^a   Jongmans, Wim ^a   Adema, Gosse J ^b   Debruyne, Frans M J ^b   de Mulder, Pieter H ^b   Oosterwijk, Egbert ^b   Mulders, Peter F A ^b  

^a Department of Urology   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dendritic cells; Immunotherapy; Interleukin 2; Renal cell carcinoma; Tumor vaccine

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD14 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; OVALBUMIN;

ADULT; AGED; ANTIGEN PRESENTING CELL; ARTICLE; CANCER IMMUNOTHERAPY; CELL LYSATE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; KIDNEY CARCINOMA; MALE; METASTASIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, RENAL CELL; CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMAN; HYPERSENSITIVITY, DELAYED; IMMUNIZATION SCHEDULE; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; INTERFERON TYPE II; INTERLEUKIN-2; INTERLEUKIN-4; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MONOCYTES; NEPHRECTOMY; RECOMBINANT PROTEINS; TREATMENT OUTCOME; VACCINATION;

EID: 19244365218     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200211000-00006     Document Type: Article

References (35)

1. Motzer RJ, Bander NH, Nanus DM, et al. Renal-cell carcinoma. New Engl J Med 1996; 335:865-75.
2. Mulders P, Figlin R, deKernion JB, et al. Renal cell carcinoma: recent progress and future directions. Cancer Res 1997; 57:5189-95.
3. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. New Engl J Med 1987; 316:889-97.
4. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon-α2a in metastatic renal cell carcinoma: an outpatient multicenter trial. J Clin Oncol 1993; 11:1809-16.
5. Melief CJM. Dendritic cells as specialized antigen-presenting cells. Res Immunol 1989; 140:902-26.
6. Steinman RM. The dendritic cells system and its role in immunogenecity. Ann Rev Immun 1991; 9:271-96.
7. Mulders P, Tso CL, Gitlitz B, et al. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin Cancer Res 1999; 5:445-54.
8. + human blood dendritic cells for active tumor immunotherapy. Exp Hematol 1997; 25:232-7.
9. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2:52-8.
10. Mukherji B, Chakraborty NG, Yamasaki S, et al. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA 1995; 92:8078-82.
11. Höltl L, Rieser C, Papesh C, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999; 161:777-82.
12. Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6:332-6.
13. Murphy G, Tjoa B, Ragde H, et al. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A2.1-specific peptidesfrom prostatic specific membrane antigen. Prostate 1996; 29:371-80.
14. Shimizu K, Fields RC, Giedlin M, et al. Systemic administration of interleukin-2 enhances the therapeutic efficacy of dendritic based vaccines. Proc Natl Acad Sci USA 1999; 96:2268-73.
15. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321-7.
16. + leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol 1996; 59:208-18.
17. Larsson M, Majeed M, Ernst D, et al. Role of annexins in endocytosis of antigens in immature human dendritic cells. Immunology 1997; 92:501-11.
18. Fong L, Brockstedt D, Benike C, et al. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001; 166:4254-9.
19. Wiebke EA, Rosenberg SA, Lotze MT. Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferative response to soluble antigens. J Clin Oncol 1988; 6:1440-9.
20. Merad M, Angevin E, Wolfers J, et al. Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biologic response modifiers (IFN-alpha plus IL-2 and IL-12). J Immunother 2000; 23:369-78.
21. Schadendorf D, Nestle FO. Autologous dendritic cells for treatment of advanced cancer—an update. Recent Results Cancer Res 2001; 158:236-48.
22. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma associated antigen G250. Int J Cancer 2000; 85:865-70.
23. Gaugler B, Brouwenstein N, Van Tomme V, et al. A new gene coding for an antigenrecognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 1996; 44:323-30.
24. Vissers JL, De Vries IJ, Schreurs MW, et al. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T Lymphocytes. Cancer Res 1999; 59:5554-9.
25. Nair SK, Snyder D, Rouse BT, et al. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997; 70:706-15.
26. Morse MA, Coleman E, Akabani G, et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999; 59:56-8.
27. Sallusto F, Lanzaveccia, A. Efficient presentation of soluble antigens by cultured human dendritic cells is maintained by Granulocyte/Macrophage Colony-stimulating factor plus Interleukin-4 and downregulated by Tumor Necrosis Factor-α. J Exp Med 1994; 179:1109-18.
28. Mellman IS, Plutner H, Steinman RM, et al. Internalization and degradation of macrophage Fc receptors during receptor-mediated phagocytosis. J Cell Biol 1983; 96:887-95.
29. Banchereau J, Steinman RM. Dendritic Cells and the control of immunity. Nature 1998; 392:245-52.
30. Barratt-Boyes SM, Zimmer, MI, Harshyne LA, et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J Immunol 2000; 164:2487-95.
31. Simons JW, Jaffee EM, Weber CE, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57:1537-46.
32. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90:3539-43.
33. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192:1213-22.
34. + blood dendritic cells as a vaccine for immunotherapy of metastatic renal-cell cancer. Lancet 1998; 352:1358-60.
35. Gitlitz B, Hinkel A, Mulders P, et al. A. Multi-antigen loaded dendritic cell vaccine for the treatment of metastatic renal cell carcinoma: in-vitro correlates (abstract 522). J Urol 1999; 161(suppl 4):1-457.